Comprehensive Report On Antibody-Drug Conjugates Clinical Trials 2024

Antibody-drug conjugates (ADCs) are targeted therapies that deliver potent drugs directly to cancer cells, minimizing damage to healthy tissue compared to traditional chemotherapy.

The ADC field is rapidly expanding, with nearly 1,000 clinical trials launched between 2019 and 2023. This growth is driven by high cancer rates, recent FDA approvals, and collaborations between pharmaceutical companies and research institutions.

Phase 2 trials dominate, comprising over 50% of the studies, with the Asia-Pacific region leading the way. Oncology remains the primary focus, accounting for 97% of trials, with tubulin inhibitors being the most common payload. However, research is also exploring ADCs for non-cancerous conditions and brain-targeted therapies.

Success in ADC development hinges on optimizing three key components: the targeting antibody, linker, and cytotoxic payload. Researchers are investigating new payloads beyond traditional chemotherapy, including immune stimulants and DNA-damaging agents.

Currently, over 200 ADCs are in development, with a focus on diversifying payloads and using bispecific antibodies to enhance effectiveness. The promising landscape of late-stage clinical trials indicates a bright future for ADCs.

The rising commercial success of ADCs is driving partnerships and acquisitions, with the market projected to reach $20 billion by 2028. However, challenges such as manufacturing complexity remain.

By overcoming these hurdles, ADCs have the potential to become a cornerstone of targeted cancer therapy. Learn more by downloading the full report below.